REFERENCES
1. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-72.
2. Bjornsson E, Gunnarsdottir K, Halldorsson GH, et al. Lifelong reduction in LDL (low-density lipoprotein) cholesterol due to a gain-of-function mutation in LDLR. Circ Genom Precis Med 2021;14:e003029.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88.
4. Ramsaran E, Preusse P, Sundaresan D, et al. Adherence to blood cholesterol treatment guidelines among physicians managing patients with atherosclerotic cardiovascular disease. Am J Cardiol 2019;124:169-75.
5. Nioi P, Sigurdsson A, Thorleifsson G, et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med 2016;374:2131-41.
6. Wang JQ, Li LL, Hu A, et al. Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion. Nature 2022;608:413-20.
